Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

This study has been completed.
Sponsor:
Collaborators:
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Information provided by (Responsible Party):
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00075829
First received: January 9, 2004
Last updated: August 3, 2016
Last verified: August 2016

January 9, 2004
August 3, 2016
December 2003
June 2012   (final data collection date for primary outcome measure)
Progression-Free Survival (PFS) [ Time Frame: Year 3 ] [ Designated as safety issue: Yes ]
Patients are considered a failure for this endpoint if they die or if they progress or relapse.
Not Provided
Complete list of historical versions of study NCT00075829 on ClinicalTrials.gov Archive Site
  • Overall Survival (OS) for Standard Risk [ Time Frame: Years 1, 2, and 3 ] [ Designated as safety issue: Yes ]
    The event is death from any cause, patients alive at the time of last observation are considered censored.
  • Overall Survival (OS) for High Risk [ Time Frame: Year 3 ] [ Designated as safety issue: Yes ]
    The event is death from any cause, patients alive at the time of last observation are considered censored.
  • Cumulative Incidence of Progression/Relapse [ Time Frame: Year 3 ] [ Designated as safety issue: Yes ]
    Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.
  • Cumulative Incidence of Treatment Related Mortality (TRM) [ Time Frame: Year 3 ] [ Designated as safety issue: Yes ]
    TRM is defined as death occurring in a patient from causes other than relapse or progression.
  • Interval From First to Second Transplantation [ Time Frame: Year 1 ] [ Designated as safety issue: Yes ]
    Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.
  • Incidences of Graft Versus Host Disease (GVHD) [ Time Frame: Day 100 ] [ Designated as safety issue: No ]
    Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.
  • Incidences of Chronic GVHD [ Time Frame: Years 1 and 2 ] [ Designated as safety issue: No ]
    Incidence and severity of chronic GVHD will be scored according to the BMT clinical trials network Manual of Procedures.
Not Provided
Not Provided
Not Provided
 
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.

Multiple myeloma (MM), characterized by malignant plasma cell proliferation, bone destruction, and immunodeficiency, is a disease with a median age at diagnosis of approximately 65 years. It is responsible for about 1 percent of all cancer-related deaths in Western Countries. Conventional treatments with chemotherapy and radiation therapy are non-curative but improve quality of life and duration of survival. Attempts to cure myeloma through high-dose therapy followed by autografting or allografting have largely failed due to a combination of relapsed disease or transplant related mortality (TRM). High-dose therapy with autologous transplantation is safe and has low TRM (less than 5%), but is associated with a continuing and nearly universal risk of disease progression and relapse. Even so, autologous transplantation is superior to continued conventional chemotherapy. Recent data indicate that tandem autologous transplants are superior to a single procedure. Even with this approach, patients remain at risk of relapse and additional approaches are needed.

DESIGN NARRATIVE:

The overall study design is that of biologic assignment, based on the availability of an HLA-matched sibling, to one of two treatment strategies for MM patients. Patients without an HLA-matched sibling will undergo tandem autologous transplants. Patients with an HLA-matched sibling will undergo an autologous transplant followed by a non-myeloablative allogeneic transplant. In addition, the tandem autologous transplant recipients will be randomized to either observation or one year of maintenance therapy to begin following the second autologous transplant. The large number of MM patients without an HLA-matched sibling enables us to evaluate the role of maintenance therapy following tandem autologous transplants.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Procedure: One Autologous Transplant
    Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive ~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) > 500/mm3 for two days.
  • Procedure: Non-Myeloablative Allogeneic Transplant
    Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
  • Procedure: Second Autologous Transplant
    Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
  • Drug: Thalidomide
    Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
    Other Name: Thalomid™
  • Drug: Dexamethasone
    Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
    Other Name: Decadron, DexPak
  • Behavioral: Observation
    One year of observation post-transplants.
  • Active Comparator: Auto transplants plus Therapy
    One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
    Interventions:
    • Procedure: One Autologous Transplant
    • Procedure: Second Autologous Transplant
    • Drug: Thalidomide
    • Drug: Dexamethasone
  • Active Comparator: Auto transplants
    One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
    Interventions:
    • Procedure: One Autologous Transplant
    • Procedure: Second Autologous Transplant
    • Behavioral: Observation
  • Active Comparator: Auto and Allo transplants
    One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
    Interventions:
    • Procedure: One Autologous Transplant
    • Procedure: Non-Myeloablative Allogeneic Transplant
    • Behavioral: Observation

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
710
March 2013
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meeting the Durie and Salmon criteria for initial diagnosis of MM
  • Stage II or III MM at diagnosis or anytime thereafter
  • Symptomatic MM requiring treatment at diagnosis or anytime thereafter
  • Received at least three cycles of initial systemic therapy and are within 2-10 months of initiation of the initial therapy (this time frame excludes the time for mobilization therapy)
  • If receiving chemotherapy-based mobilization regimens, must be able to receive high-dose melphalan between 2 and 8 weeks after the initiation of mobilization therapy whether delivered at the transplant center or at a referring center
  • Adequate organ function as measured by:

    1. Cardiac: Left ventricular ejection fraction at rest greater than 40%
    2. Hepatic: Bilirubin less than 2 times the upper limit of normal and alanine transaminase (ALT) and aspartate transaminase (AST) less than 3 times the upper limit of normal
    3. Renal: Creatinine clearance greater than 40 ml/min (measured or calculated/estimated)
    4. Pulmonary: Carbon monoxide diffusion (DLCO), Volume forcibly exhaled in one second (FEV1), and Forced Vital Capacity (FVC) greater than 50% of predicted value (corrected for hemoglobin), or O2 saturation greater than 92% of room air
  • An adequate autologous graft defined as a cryopreserved PBSC graft containing at least 4.0 x 106 CD34+ cells/kg patient weight; if prior to enrollment it is known that a patient will be on the auto-allo arm (i.e., a consenting, eligible HLA-matched sibling donor is available), the required autograft must contain at least 2.0 x 10^6 CD34+ cells/kg patient weight; the graft may not be CD34+ selected or otherwise manipulated to remove tumor or other cells; the graft can be collected at the transplanting institution or by a referring center; for patients without an HLA-matched sibling donor, the autograft must be stored so that there are two products each containing at least 2 x 10^6 CD34+ cells/kg patient weight

Exclusion Criteria:

  • Never advanced beyond Stage I MM since diagnosis
  • Non-secretory MM (absence of a monoclonal protein [M protein] in serum as measured by electrophoresis and immunofixation and the absence of Bence Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques)
  • Plasma cell leukemia
  • Karnofsky performance score less than 70%, unless approved by the Medical Monitor or one of the Protocol Chairs
  • Uncontrolled hypertension
  • Uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms)
  • Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Medical Monitor or one of the Protocol Chairs; cancer treated with curative intent more than 5 years previously will be allowed
  • Pregnant or breastfeeding
  • Seropositive for the human immunodeficiency virus (HIV)
  • Unwilling to use contraceptive techniques during and for 12 months following treatment
  • Prior allograft or prior autograft
  • Received mid-intensity melphalan (more than 50 mg IV) as part of prior therapy
  • Prior organ transplant requiring immunosuppressive therapy
Both
up to 70 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00075829
BMTCTN0102, BMT CTN 0102, SUMC-79730, 417
No
Yes
Findings will be published in a manuscript
National Heart, Lung, and Blood Institute (NHLBI)
National Heart, Lung, and Blood Institute (NHLBI)
  • Blood and Marrow Transplant Clinical Trials Network
  • National Cancer Institute (NCI)
  • National Marrow Donor Program
Study Director: Mary Horowitz, MD Center for International Blood and Marrow Transplant Research
National Heart, Lung, and Blood Institute (NHLBI)
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP